On August 27, WUXI BIO fell 3.05% in regular trading, trading at HKD 49.16 per share, with turnover of HKD 1.097 billion.

On the news front, the company released strong interim results on August 25 and raised its full-year guidance, driving the stock up sharply over two consecutive sessions. With short-term cumulative gains being substantial, some investors opted to lock in profits. Multiple investment banks had previously raised their target prices for WUXI BIO, and fundamental expectations were considered fully reflected in the price.

The broader CXO sector weakened collectively, with peers Pharmaron down 5.5%, WUXI XDC down 4.98%, GenScript Bio down 4.3%, and WuXi AppTec down 1.05%, indicating a sector-wide correction. The company's mid-year results showed revenue of RMB 117.87 billion, up 18.4% year-over-year, and adjusted net profit attributable to shareholders of RMB 3.306 billion, up 38.4%, with three-year backlog reaching approximately USD 5.5 billion, up approximately 30%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)